Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.76 EUR
Change Today +0.59 / 4.88%
Volume 0.0
RAH On Other Exchanges
As of 12:55 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (RAH) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €15.59
52 Week Low
12/16/14 - €1.88
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RECRO PHARMA INC (RAH)

Related News

No related news articles were found.

recro pharma inc (RAH) Related Businessweek News

No Related Businessweek News Found

recro pharma inc (RAH) Details

Recro Pharma, Inc., a clinical stage specialty pharmaceutical company, engages in developing non-opioid therapeutics for the treatment of pain. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex to the treatment of chronic pain; and Fadolmidine(Fado) for post-operative and/or neuropathic pain. It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fado. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.

5 Employees
Last Reported Date: 04/2/15
Founded in 2007

recro pharma inc (RAH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $490.4K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $320.5K
Senior Vice President of Development and Secr...
Total Annual Compensation: $255.2K
Compensation as of Fiscal Year 2014.

recro pharma inc (RAH) Key Developments

Recro Pharma, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Recro Pharma, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $18,660,000. Operating income was $373,000 compared with operating loss of $2,796,000 for the same period a year ago. Net loss applicable to common shareholders was $1,311,000 or $0.17 per basic and diluted share compared with $2,794,000 or $0.36 per basic and diluted share for the same period a year ago. For the six months, the company reported total revenues of $18,660,000. Operating loss was $3,770,000 compared with $3,670,000 for the same period a year ago. Net loss applicable to common shareholders was $5,450,000 or $0.70 per basic and diluted share compared with $9,210,000 or $1.94 per basic and diluted share for the same period a year ago. There were no revenues and costs of sales in the comparable periods in 2014. The increases in revenues and costs of sales were the result of the acquired manufacturing business from Alkermes.

Recro Pharma Appoints Scott Rizzo as General Manager

Recro Pharma, Inc. announced the appointment of Scott Rizzo as General Manager of the company's contract manufacturing facility located in Gainesville, Georgia. Scott brings 25 years of experience and a seasoned manufacturing background to Recro Pharma at an important and exciting time for the company. Mr. Rizzo joins Recro Pharma from J. Knipper where he served as General Manager.

Recro Pharma, Inc. Announces Positive Results for Phase II Clinical Trial of Dex-IN

Recro Pharma, Inc. announced positive efficacy results in the Phase II clinical trial for Dex-IN, a proprietary intranasal formulation of dexmedetomidine, for the treatment of acute pain in adult patients undergoing bunionectomy surgery. Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The company plans to meet with the FDA to discuss the Company's Phase III plans and determine what, if any, additional information will be required in association with the Phase III clinical program for Dex-IN. The Phase II trial was a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who met the eligibility criteria were randomized to either a 50 g dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remained under observation for 48 hours at study centers. Patients were followed for 7 days after the initial dose of study medication. There was an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. A total of 168 patients were randomized and received study medication in the clinical trial, 84 patients in each treatment group. Seven patients discontinued the study early, six for lack of efficacy (three in each treatment group) and one for a serious adverse event of hypotension. The primary efficacy endpoint of the trial was the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints included use of opioid rescue medication, SPIDs over various time intervals, as well as other standard efficacy analyses. The most common adverse events observed in the study were blood pressure decrease /hypotension, nausea (similar incidences to placebo), nasal discomfort and headache. An adverse event of bradycardia was reported in 3 subjects in the Dex-IN treatment group.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAH:GR €12.76 EUR +0.59

RAH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAH.
View Industry Companies

Industry Analysis


Industry Average

Valuation RAH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.5x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at